WuXi Biologics
Offering End-to-End Solutions
WuXi Biologics offers comprehensive mammalian cell line development (CLD) capabilities for various biotherapeutics. Our program typically starts with client-provided DNA or protein sequences and ends with the delivery of high-yielding, well-characterized, stable single clones. The Chinese word “WuXia” translates to “flawless or ideal” in English. Hence, this is why we chose to name our cell line development (CLD) platform “WuXia.”
Industry-leading CLD
CHO-K1 |
Timeline
(DNA to MCB*) |
Average
Productivity |
Average
Productivity |
9-10 weeks
|
3.3 g/L (Pool)
|
5.6 g/L (Clone)
|
*Timeline to the initiation of MCB generation
Over 300 cell lines developed and 50+ submitted in Global INDs